Brigitte C. Widemann
Led the selumetinib trials that gave children with neurofibromatosis their first approved drug.
Paediatric oncologist whose NF1 plexiform neurofibroma studies led to selumetinib's approval, and who leads NCI's paediatric oncology branch and rare tumour initiatives.
| Title | Journal | Year |
|---|---|---|
| Selumetinib in children with inoperable plexiform neurofibromas | New England Journal of Medicine | 2020 |
Pages like this
not linked directly; found by shared links- IdeaPay a prize for rare cancer drugs instead of hoping for a market
Shares Neuroblastoma (paediatric), National Cancer Institute (NIH), Sarcomas (soft tissue, bone, GIST).
- PersonLouis M. Staudt
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
- PersonJames L. Gulley
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
- PersonRaffit Hassan
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
- PersonNirali N. Shah
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
- IdeaAn open organoid bank for cancers too rare to have models
Shares Neuroblastoma (paediatric), National Cancer Institute (NIH), Sarcomas (soft tissue, bone, GIST).
- IdeaPet dogs with spontaneous cancer as a bridge before human trials
Shares National Cancer Institute (NIH), Sarcomas (soft tissue, bone, GIST).
- IdeaOpen-source drug discovery to clinical proof of concept for neglected cancers
Shares Neuroblastoma (paediatric), Sarcomas (soft tissue, bone, GIST).